Market News & Trends
Jazz Pharmaceuticals & Zymeworks Announce Exclusive License Agreement
Jazz Pharmaceuticals plc and Zymeworks Inc. recently announced Jazz and Zymeworks’ subsidiary, Zymeworks BC Inc., have entered into an exclusive licensing agreement under which Jazz will acquire….
Societal CDMO Announces Signing of Multiple New CDMO Service Agreements
Societal CDMO, Inc. recently announced it has signed CDMO service agreements with two new customers. These contracts are focused on a range of analytical method, technical transfer, formulation, manufacturing and….
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Preclinical Study
Silo Pharma, Inc. recently announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer's disease (AD), as demonstrated in a mouse…
Aragen to Operationalize Cutting-Edge Formulation Manufacturing Facility
Aragen recently announced it will operationalize its state-of-the-art formulation manufacturing facility in the Mallapur campus, Hyderabad, India, by January 2023. The 12,000-sq-ft new facility will…
Pistoia Alliance Launches Global Community of Interest to Assess the Environmental Impact of Clinical Trials
The Pistoia Alliance recently announced the launch of the Clinical Trials Environmental Impact Community of Interest (CoI) to measure and compare the carbon footprint of centralized (traditional site-based) and decentralized clinical trials…..
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Crinetics Pharmaceuticals, Inc. recently announced the completion of enrollment in the Phase 3 PATHFNDR-1 study. PATHFNDR-1 is one of two ongoing, placebo-controlled Phase 3 studies evaluating…
VBI Vaccines & Agenus Announce Collaboration to Evaluate VBI-1901 in Combination With Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
VBI Vaccines Inc. and Agenus recently announced a collaboration to evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, and balstilimab, Agenus’ monoclonal….
Thermo Fisher Scientific Unveils New Clinical Research Laboratory in Virginia
Thermo Fisher Scientific recently expanded its clinical research operations with the opening of a state-of-the art bioanalytical lab in Richmond, VA. The new unit will…
Tavros Therapeutics & Vividion Therapeutics Announce Strategic Collaboration to Discover & Enhance Targeted Oncology Programs
Tavros Therapeutics and Vividion Therapeutics, Inc. recently announced the companies have entered into a collaboration agreement to discover or target four oncology targets across an initial 5-year term…..
BriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients
BriaCell Therapeutics Corp. recently announced today it has added Mayo Clinic, Jacksonville, FL, as a clinical site in the Phase 1/2 study of BriaCell’s lead…
Syneos Health Expands Partnership With Datavant to Accelerate Delivery of New Therapies to Patients
Syneos Health recently announced an expanded partnership with Datavant, the leader in helping organizations securely connect health data. The increasing collaboration between the companies will further leverage….
Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients With Krabbe Disease
Forge Biologics recently announced Chief Medical Officer Maria Escolar, MD, MS, presented updated clinical data from the RESKUE Phase 1/2 clinical trial for FBX-101—the company’s…
HUTCHMED Initiates a Phase 2/3 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia
HUTCHMED (China) Limited recently announced it has initiated a Phase 2/3 trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia….
FDA Approves New Treatment Option for Patients With ALS
The US FDA approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease. “This approval provides another…
Evonik & Phathom Pharmaceuticals Partner to Produce Novel Acid-Blocker Vonoprazan
Evonik has entered into a long-term supply agreement with Phathom Pharmaceuticals, a US biopharmaceutical company focused on developing and commercializing new treatments for gastric acid-related…
Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Investigational Hormone-Free Monthly Intravaginal Contraceptive
Daré Bioscience, Inc. recently announced the US FDA approved an Investigational Device Exemption (IDE) application allowing Daré to conduct a single arm, open-label pivotal contraceptive…
Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia
Silo Pharma, Inc. recently announced it has initiated a preclinical toxicity study of its novel time-released, dosage controlled formulation of ketamine, designated as….
Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of Nasal Naltrexone in Patients With Alcohol Use Disorder
Opiant Pharmaceuticals, Inc. recently announced the last patient has been enrolled in the Phase 2 clinical trial of OPNT002, nasal naltrexone, for patients with….
Two Cell & Gene Therapies Manufactured at Lonza Houston Reach US FDA Approval
Lonza recently announced two additional cell and gene therapies manufactured at its Houston (US) site have reached commercial approval in Q3 2022. ZYNTEGLO, for the…
Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy
Mustang Bio, Inc. recently announced the first patient has been treated in its multicenter, open-label, non-randomized Phase 1/2 clinical trial evaluating the safety and efficacy…
